8-K
filed February 28, 2025, 6:59 PM ET
CIK 0001556263
other material
confidence high
sentiment negative
materiality 1.00
Syros Pharmaceuticals to voluntarily delist from Nasdaq; CEO Quirk steps down, wind-down underway
Syros Pharmaceuticals, Inc.
- Voluntary delisting from Nasdaq; Form 25 to be filed ~March 10, 2025, effective ~March 20; intends to file Form 15 to suspend SEC reporting.
- CEO Gerald Quirk steps down as CEO/President effective March 1; remains on Board as director and consultant.
- Directors Peter Wirth, Marsha Fanucci, Nancy Simonian resign from Board effective immediately; no disagreement.
- Matthew Foster appointed Chief Restructuring Officer effective March 1 to oversee wind-down.
- Wind-down triggered by Phase 3 trial (SELECT-MDS-1) failure and default under Oxford Finance loan; operating under Oxford-approved budget.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Gerald Quirk departed as Chief Executive Officer and President at Syros Pharmaceuticals, Inc..
- Action
- cease to serve
- Role
- Chief Executive Officer and President
Exact text from the filing
Effective March 1, 2025, Gerald Quirk will cease to serve as Chief Executive Officer and President of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Marsha H. Fanucci resigned as Director at Syros Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On February 28, 2025, each of Peter Wirth, Marsha H. Fanucci, and Nancy Simonian, M.D., notified the Board of such director’s resignation from the Board and all committees or subcommittees thereof, effective immediately.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Nancy Simonian resigned as Director at Syros Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On February 28, 2025, each of Peter Wirth, Marsha H. Fanucci, and Nancy Simonian, M.D., notified the Board of such director’s resignation from the Board and all committees or subcommittees thereof, effective immediately.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Peter Wirth resigned as Director at Syros Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On February 28, 2025, each of Peter Wirth, Marsha H. Fanucci, and Nancy Simonian, M.D., notified the Board of such director’s resignation from the Board and all committees or subcommittees thereof, effective immediately.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Gerald Quirk was appointed as Director at Syros Pharmaceuticals, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
On February 28, 2025, Gerald Quirk was appointed to the Board.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.